BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Kidney
,
DNA fingerprint
,
Tamoxifen
,
rs2476601
,
MDM2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
WEE 1. 3
Summary
General Info
Curated Studies
Most Correlated Studies
Acute monocytic leukemia cell lines in response to ABT-869, SAHA, or combined inhibitor treatments
Multiple myeloma cells response to 3-Deazaneplanocin A (DZNep)
Mammary gland SK-BR-3 cells with TALEN-mediated knockout of MIR141 and/or MIR200C
Blood monocytes from healthy individuals treated with niacin
Brain tumor initiating BT025 cells treated with tenascin C
Explore Curated Studies Results
Literature
Most Relevant Literature
Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1.
PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.
PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
CCNE1 Amplification and PKMYT1 Inhibition Are Synthetic Lethal.
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine
Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ova…
Functional Recovery in Critically Ill Children, the Wee-Cover Multicentre Study
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Me…
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ